Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

480

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Pulmonary Hypertension Associated With Interstitial Lung Disease

Interventions

DRUG

Placebo

Matching capsule containing placebo

DRUG

Seralutinib

Capsule containing seralutinib

DEVICE

Generic Dry Powder Inhaler

Generic dry powder inhaler for seralutinib or placebo delivery

All Listed Sponsors

collaborator

Chiesi Farmaceutici S.p.A.

INDUSTRY

lead

GB002, Inc.

INDUSTRY